Fact Source: Financial Supervisory Service DART / 2025-12-12
Disclosure Type: Execution of Single Sales/Supply Contract (Correction)
💡 3-Second Summary
Samsung Biologics has announced that the confidentiality expiration date regarding its 2019 pharmaceutical Contract Manufacturing Organization (CMO) agreement with UCB has been extended from the end of 2025 to the end of 2031 following the client’s request.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Original Filing Date & Target: Corrective filing for the Single Sales/Supply Contract originally submitted on 2019-05-17.
- Reason for Correction: Extension of the operational nondisclosure period driven by the client’s request for confidentiality.
- Corrected Item (Confidentiality Term):
- Expiration Date: Before: 2025-12-31 → After: 2031-12-31
- Original Contract Parameters:
- Counterparty: UCB
- Contract Title: Contract Manufacturing Agreement for Pharmaceuticals (Other Sales/Supply Contract)
- Contract Amount: KRW 40,250,652,017 (Reflects the confirmed revenue of USD 33,829,763 recognized through 2021, converted using the historical exchange rate of KRW 1,189.80/USD as of May 17, 2019)
- Ratio to Revenue: 7.51% (Compared to the baseline revenue of KRW 535,805,801,067 from the 2018 financial statements)
- Contract Period: Start Date: 2019-05-17 / End Date and final value are subject to change by mutual agreement and are unrecorded (-).
- Other Critical Parameters (Including Revisions):
- If the client successfully develops the contract product, the fixed minimum guaranteed contract amount is scheduled to increase to USD 147,656,263.
- The fixed minimum guaranteed contract amount may further increase upon mutual agreement if client demand scales up.
- The final contract duration is scheduled to be disclosed after December 31, 2031, due to operational confidentiality.
- The original contract execution date was 2019-05-17. The disclosure does not state specific reasons for the change in earnings performance.
📈 2. [Expert View: What This Disclosure Means for Investors]
This regulatory filing is an administrative amendment adjusting the reporting timeline of an existing 2019 manufacturing ledger, rather than an entirely new pipeline addition or an immediate cross-border CAPEX expansion. Extending the confidentiality block by six additional years until late 2031 under UCB’s requirement indicates a strategic alignment meant to secure client relations.
The foundational data point for investors to evaluate is the conditional expansion framework appended to the text. The filing notes that upon the client’s successful development of the underlying therapeutic product, the fixed minimum guaranteed valuation will scale up to USD 147.66M (representing roughly KRW 175.7B under the historical baseline rate), which introduces a potential impact regarding long-term revenue step-ups. However, because the exact contract end dates and ongoing durations are completely locked under this confidentiality shield until 2031, near-term public evaluation of this backlog remains restricted. Investors should evaluate this occurrence based on the long-term structural value of the conditional upside clauses rather than introducing speculative near-term financial adjustments.
📝 Editor’s Comment (by K-STOCK Editor)
Samsung Biologics’ latest corrective filing represents a standard procedural timeline calibration adjusting an existing relationship established with UCB back in 2019. Pushing back the disclosure expiration date from December 2025 to December 2031 means the structural details of this manufacturing allocation will remain unrecorded for public markets for another six years. While this technical extension triggers zero immediate impact on trailing financial positions, the confirmation of a conditional price step-up to USD 147.6M upon successful product development remains a key structural mechanism. Global investors should look past immediate baseline tracking and maintain a long-term perspective regarding the sequential execution of these conditional underlying targets.
📢 Disclaimer & Source Information
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the individual investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
